Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy
- 31 December 2008
- journal article
- Published by Elsevier in Advances in Enzyme Regulation
- Vol. 48 (1) , 113-135
- https://doi.org/10.1016/j.advenzreg.2008.02.006
Abstract
No abstract availableKeywords
This publication has 159 references indexed in Scilit:
- Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistanceBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2007
- A transforming mutation in the pleckstrin homology domain of AKT1 in cancerNature, 2007
- Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignanciesPublished by Elsevier ,2007
- Patterns of somatic mutation in human cancer genomesNature, 2007
- Ubiquitination Regulates PTEN Nuclear Import and Tumor SuppressionCell, 2007
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004
- Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPKNature Cell Biology, 2003
- Rheb is a direct target of the tuberous sclerosis tumour suppressor proteinsNature Cell Biology, 2003
- Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancersNature Genetics, 1997
- Phosphatidylinositol-3-OH kinase direct target of RasNature, 1994